Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy

Allison C. Sharrow, Brandy Perkins, Michael I. Collector, Wei Yu, Brian W. Simons, Richard J Jones

Research output: Contribution to journalArticle

Abstract

Objective The cancer stem cell (CSC) paradigm hypothesizes that successful clinical eradication of CSCs may lead to durable remission for patients with ovarian cancer. Despite mounting evidence in support of ovarian CSCs, their phenotype and clinical relevance remain unclear. We and others have found high aldehyde dehydrogenase 1 (ALDHhigh) expression in a variety of normal and malignant stem cells, and sought to better characterize ALDHhigh cells in ovarian cancer. Methods We compared ALDHhigh to ALDHlow cells in two ovarian cancer models representing distinct subtypes: FNAR-C1 cells, derived from a spontaneous rat endometrioid carcinoma, and the human SKOV3 cell line (described as both serous and clear cell subtypes). We assessed these populations for stem cell features then analyzed expression by microarray and qPCR. Results ALDHhigh cells displayed CSC properties, including: smaller size, quiescence, regenerating the phenotypic diversity of the cell lines in vitro, lack of contact inhibition, nonadherent growth, multi-drug resistance, and in vivo tumorigenicity. Microarray and qPCR analysis of the expression of markers reported by others to enrich for ovarian CSCs revealed that ALDHhigh cells of both models showed downregulation of CD24, but inconsistent expression of CD44, KIT and CD133. However, the following druggable targets were consistently expressed in the ALDHhigh cells from both models: mTOR signaling, her-2/neu, CD47 and FGF18/FGFR3. Conclusions Based on functional characterization, ALDHhigh ovarian cancer cells represent an ovarian CSC population. Differential gene expression identified druggable targets that have the potential for therapeutic efficacy against ovarian CSCs from multiple subtypes.

Original languageEnglish (US)
Pages (from-to)341-348
Number of pages8
JournalGynecologic Oncology
Volume142
Issue number2
DOIs
StatePublished - Aug 1 2016

Fingerprint

Cell- and Tissue-Based Therapy
Ovarian Neoplasms
Stem Cells
Neoplastic Stem Cells
Contact Inhibition
Endometrioid Carcinoma
Cell Line
aldehyde dehydrogenase 1
Multiple Drug Resistance
Microarray Analysis
Population
Down-Regulation
Phenotype
Gene Expression
Growth

Keywords

  • Aldehyde dehydrogenase 1
  • Cancer stem cells
  • Ovarian cancer
  • Stem cell-targeted therapy

ASJC Scopus subject areas

  • Oncology
  • Obstetrics and Gynecology

Cite this

Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells : Towards targeted stem cell therapy. / Sharrow, Allison C.; Perkins, Brandy; Collector, Michael I.; Yu, Wei; Simons, Brian W.; Jones, Richard J.

In: Gynecologic Oncology, Vol. 142, No. 2, 01.08.2016, p. 341-348.

Research output: Contribution to journalArticle

Sharrow, Allison C. ; Perkins, Brandy ; Collector, Michael I. ; Yu, Wei ; Simons, Brian W. ; Jones, Richard J. / Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells : Towards targeted stem cell therapy. In: Gynecologic Oncology. 2016 ; Vol. 142, No. 2. pp. 341-348.
@article{9a5021a7b7974a0eb5c080b2b5dfe4c8,
title = "Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells: Towards targeted stem cell therapy",
abstract = "Objective The cancer stem cell (CSC) paradigm hypothesizes that successful clinical eradication of CSCs may lead to durable remission for patients with ovarian cancer. Despite mounting evidence in support of ovarian CSCs, their phenotype and clinical relevance remain unclear. We and others have found high aldehyde dehydrogenase 1 (ALDHhigh) expression in a variety of normal and malignant stem cells, and sought to better characterize ALDHhigh cells in ovarian cancer. Methods We compared ALDHhigh to ALDHlow cells in two ovarian cancer models representing distinct subtypes: FNAR-C1 cells, derived from a spontaneous rat endometrioid carcinoma, and the human SKOV3 cell line (described as both serous and clear cell subtypes). We assessed these populations for stem cell features then analyzed expression by microarray and qPCR. Results ALDHhigh cells displayed CSC properties, including: smaller size, quiescence, regenerating the phenotypic diversity of the cell lines in vitro, lack of contact inhibition, nonadherent growth, multi-drug resistance, and in vivo tumorigenicity. Microarray and qPCR analysis of the expression of markers reported by others to enrich for ovarian CSCs revealed that ALDHhigh cells of both models showed downregulation of CD24, but inconsistent expression of CD44, KIT and CD133. However, the following druggable targets were consistently expressed in the ALDHhigh cells from both models: mTOR signaling, her-2/neu, CD47 and FGF18/FGFR3. Conclusions Based on functional characterization, ALDHhigh ovarian cancer cells represent an ovarian CSC population. Differential gene expression identified druggable targets that have the potential for therapeutic efficacy against ovarian CSCs from multiple subtypes.",
keywords = "Aldehyde dehydrogenase 1, Cancer stem cells, Ovarian cancer, Stem cell-targeted therapy",
author = "Sharrow, {Allison C.} and Brandy Perkins and Collector, {Michael I.} and Wei Yu and Simons, {Brian W.} and Jones, {Richard J}",
year = "2016",
month = "8",
day = "1",
doi = "10.1016/j.ygyno.2016.03.022",
language = "English (US)",
volume = "142",
pages = "341--348",
journal = "Gynecologic Oncology",
issn = "0090-8258",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Characterization of aldehyde dehydrogenase 1 high ovarian cancer cells

T2 - Towards targeted stem cell therapy

AU - Sharrow, Allison C.

AU - Perkins, Brandy

AU - Collector, Michael I.

AU - Yu, Wei

AU - Simons, Brian W.

AU - Jones, Richard J

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Objective The cancer stem cell (CSC) paradigm hypothesizes that successful clinical eradication of CSCs may lead to durable remission for patients with ovarian cancer. Despite mounting evidence in support of ovarian CSCs, their phenotype and clinical relevance remain unclear. We and others have found high aldehyde dehydrogenase 1 (ALDHhigh) expression in a variety of normal and malignant stem cells, and sought to better characterize ALDHhigh cells in ovarian cancer. Methods We compared ALDHhigh to ALDHlow cells in two ovarian cancer models representing distinct subtypes: FNAR-C1 cells, derived from a spontaneous rat endometrioid carcinoma, and the human SKOV3 cell line (described as both serous and clear cell subtypes). We assessed these populations for stem cell features then analyzed expression by microarray and qPCR. Results ALDHhigh cells displayed CSC properties, including: smaller size, quiescence, regenerating the phenotypic diversity of the cell lines in vitro, lack of contact inhibition, nonadherent growth, multi-drug resistance, and in vivo tumorigenicity. Microarray and qPCR analysis of the expression of markers reported by others to enrich for ovarian CSCs revealed that ALDHhigh cells of both models showed downregulation of CD24, but inconsistent expression of CD44, KIT and CD133. However, the following druggable targets were consistently expressed in the ALDHhigh cells from both models: mTOR signaling, her-2/neu, CD47 and FGF18/FGFR3. Conclusions Based on functional characterization, ALDHhigh ovarian cancer cells represent an ovarian CSC population. Differential gene expression identified druggable targets that have the potential for therapeutic efficacy against ovarian CSCs from multiple subtypes.

AB - Objective The cancer stem cell (CSC) paradigm hypothesizes that successful clinical eradication of CSCs may lead to durable remission for patients with ovarian cancer. Despite mounting evidence in support of ovarian CSCs, their phenotype and clinical relevance remain unclear. We and others have found high aldehyde dehydrogenase 1 (ALDHhigh) expression in a variety of normal and malignant stem cells, and sought to better characterize ALDHhigh cells in ovarian cancer. Methods We compared ALDHhigh to ALDHlow cells in two ovarian cancer models representing distinct subtypes: FNAR-C1 cells, derived from a spontaneous rat endometrioid carcinoma, and the human SKOV3 cell line (described as both serous and clear cell subtypes). We assessed these populations for stem cell features then analyzed expression by microarray and qPCR. Results ALDHhigh cells displayed CSC properties, including: smaller size, quiescence, regenerating the phenotypic diversity of the cell lines in vitro, lack of contact inhibition, nonadherent growth, multi-drug resistance, and in vivo tumorigenicity. Microarray and qPCR analysis of the expression of markers reported by others to enrich for ovarian CSCs revealed that ALDHhigh cells of both models showed downregulation of CD24, but inconsistent expression of CD44, KIT and CD133. However, the following druggable targets were consistently expressed in the ALDHhigh cells from both models: mTOR signaling, her-2/neu, CD47 and FGF18/FGFR3. Conclusions Based on functional characterization, ALDHhigh ovarian cancer cells represent an ovarian CSC population. Differential gene expression identified druggable targets that have the potential for therapeutic efficacy against ovarian CSCs from multiple subtypes.

KW - Aldehyde dehydrogenase 1

KW - Cancer stem cells

KW - Ovarian cancer

KW - Stem cell-targeted therapy

UR - http://www.scopus.com/inward/record.url?scp=84990193326&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84990193326&partnerID=8YFLogxK

U2 - 10.1016/j.ygyno.2016.03.022

DO - 10.1016/j.ygyno.2016.03.022

M3 - Article

C2 - 27017984

AN - SCOPUS:84990193326

VL - 142

SP - 341

EP - 348

JO - Gynecologic Oncology

JF - Gynecologic Oncology

SN - 0090-8258

IS - 2

ER -